1. Record Nr. UNINA9910786043603321

Autore	Axelrod C. Warren
Titolo	Engineering safe and secure software systems / / C. Warren Axelrod
Pubbl/distr/stampa	Boston : , : Artech House, , [2013] [Piscataqay, New Jersey] : , : IEEE Xplore, , [2012]
ISBN	1-60807-473-0
Descrizione fisica	1 online resource (349 p.)
Collana	Artech House information security and privacy series
Disciplina	620.001/171
Soggetti	Software engineering Systems engineering
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	1. Introduction -- 2. Engineering Systems -- 3. Engineering Software Systems -- 4. Engineering Secure and Safe Systems, Part 1 -- 5. Secure and Safe Systems, Part 2 -- Secure and Safe Systems, Part 2 -- 6. Software Systems Security and Safety Risk -- 7. Software System Security and Safety Metrics -- 8. Software System Development Processes -- 9. Secure SSDLC Projects in Greater Detail -- 10. Safe SSDLC Projects in Greater Detail -- 11. The Economics of Software Systems' Safety and Security -- Appendices.
Sommario/riassunto	"This first-of-its-kind resource offers a broad and detailed understanding of software systems engineering from both security and safety perspectives. Addressing the overarching issues related to safeguarding public data and intellectual property, the book defines such terms as systems engineering, software engineering, security, and safety as precisely as possible, making clear the many distinctions, commonalities, and interdependencies among various disciplines. You explore the various approaches to risk and the generation and analysis of appropriate metrics. This unique book explains how processes relevant to the creation and operation of software systems should be determined and improved, how projects should be managed, and how products can be assured. You learn the importance of integrating safety and security into the development life cycle. Additionally, this practical volume helps identify what motivators and deterrents can be put in

		place in order to implement the methods that have been recommended."

2.	Record Nr.	UNINA9910781469203321
	Titolo	Current issues in Romance languages : selected papers from the 29th Linguistic Symposium on Romance Languages (LSRL), Ann Arbor, 8-11 April 1999 / / edited by Teresa Satterfield, Christina Tortora, Diana Cresti
	Pubbl/distr/stampa	Amsterdam ; ; Philadelphia : , : J. Benjamins Pub., , 2002 ©2002
	ISBN	1-283-31219-0 9786613312198 90-272-7543-2
	Descrizione fisica	1 online resource (vi, 403 pages)
	Collana	Amsterdam studies in the theory and history of linguistic science. Series IV, Current issues in linguistic theory, , 0304-0763 ; ; v. 220
	Altri autori (Persone)	SatterfieldTeresa <1965-> TortoraChristina CrestiDiana
	Disciplina	440
	Soggetti	Romance languages
	Lingua di pubblicazione	Inglese
	Formato	Materiale a stampa
	Livello bibliografico	Monografia
	Nota di bibliografia	Includes bibliographical references and index.
	Nota di contenuto	CURRENT ISSUES IN ROMANCE LANGUAGES; Editorial page; Title page; Copyright page; Table of contents; PREFACE; ON BECOMING A CLITIC: THE PRENOMINAL POSSESSIVE IN ROMANCE; 0. Introduction; 1. Latin roots; 2. Development from Latin; 2.1 Old French; 2.2 Old Spanish; 2.3 Italian; 3. Syntactic Representation; 4. Conclusion; REFERENCES; PRIMARY STRESS IN SPANISH; 0. Introduction; 1. Data; 2. Test; 3. Analysis; 3.1 Lexical patterns; 3.2 Quantity sensitivity; 3. 3 Falling diphthongs; 3.4 A process in change; 4. Ternary Feet; 5. Conclusion; REFERENCES; SPANISH CLAUSES WITHOUT COMPLEMENTIZER 1. Introduction 2. Spanish clauses without complementizer; 3. On the presence or absence of the CP projection; 3.1 Topicalization; 3.2 Wh-

extraction; 4. On the impossibility of a pre-verbal subject in complementizerless clauses; 5. Conclusion; REFERENCES; ON THE NATURE OF BARE NOUNS IN HAITIAN CREOLE; 1. Introduction; 2. Theoretical Background; 3. The properties of Haitian Creole bare Nouns; 4. HC bare nouns in Chierchia's typology; 5. Evidence for a null determiner in HC; 6. The syntax and semantics of the Haitian Creole null D°; REFERENCES; TOWARDS A SYNTAX OF ADULT ROOT INFINITIVES 0. Introduction 1. Syntactic properties; 1.1 Adverb placement; 1.2 Left periphery; 1.3 Clausal structure; 2. Some differences; 2.1 Temporal interpretation; 2.2 Topic constructions; 2.3 Subject properties; 2.4 Infinitival raising; 3. Syntactic analysis; 4. Conclusion; REFERENCES; RE-EXAMINING SPANISH 'RESYLLABIFICATION'; 1. Introduction; 2. Data; 3. The Status of Spanish Prefixes; 4. A Theoretical Analysis of Spanish Syllabification; 5. Previous Analyses and Their Shortcomings; 6. Conclusion; REFERENCES; ON PREVERBAL SUBJECTS IN SPANISH; 0. Introduction; 1. Spanish preverbal subjects
2. Evidence that preverbal subjects are not in topic position 3. Focus/wh-phrases; 4. Evidence that preverbal subjects are not in focus/wh- position; 5. Towards a solution; 6. Conclusions; REFERENCES; THE SEMANTICS OF SPANISH FREE RELATIVES; 1. The morphological encoding of quantificational force; 2. Indefinite FRs; 3. Definite vs. universal FRs; 4. The semantic interpretation of FRs; REFERENCES; SPLIT SUBJECT PRONOUN PARADIGMS: FEATURE GEOMETRY AND UNDER SPECIFICATION; 0. Introduction; 1. Linguistic Atlas Data; 2. How many parameters?; 3. Feature Geometry; 4. Underspecification
4.1 The tu ~ vous split 5. Splitting the Geometry; 6. Conclusion; REFERENCES; LOCATIVE INVERSION, PP TOPICALIZATION AND THE EPP; 0. Introduction; 1. The transitivity restriction in English; 2. Agr as [+D] head in Spanish; 3. Locative subjects vs. fronted locative PPs in Spanish; 4. PP fronting in Italian; 5. Conclusion; REFERENCES; CONTRAST MAINTENANCE AND INTERVOCALIC STOP LENITION IN SPANISH AND PORTUGUESE: WHEN IS IT ALRIGHT TO LENITE?; 0. Introduction; 1. Lenition Processes; 2. The phonetic implementation of intervocalic stops in Spanish and Portuguese; 3. Experimental design; 4. Results; 5. Conclusions

Sommario/riassunto

This book presents an enlightening collection of papers contributing to theoretical discussions across many topics within the study of Romance Languages and Linguistics. The work originates from the 29th Linguistic Symposium on Romance Languages held in 1999 at the University of Michigan-Ann Arbor, although only a small subpart of the proceedings papers are included in this volume. The selected papers have been reworked for the current publication.

3.	Record Nr.	UNINA9910839791803321
	Autore	Picardi, Filippo
	Titolo	Morale e filosofia della morale in Erminio Juvalta / Filippo Picardi
	Pubbl/distr/stampa	Milano, : Marzorati, copyr. 1978
	Descrizione fisica	220 p. ; 24 cm
	Collana	Pubblicazioni dell'Istituto di filosofia, Facoltà di magistero dell'Università di Genova ; 24
	Disciplina	171
	Locazione	FLFBC
	Collocazione	DAM A70 PICF 01
	Lingua di pubblicazione	Italiano
	Formato	Materiale a stampa
	Livello bibliografico	Monografia

4.	Record Nr.	UNINA9911020083103321
	Autore	Corey E. J
	Titolo	Molecules Engineered Against Oncogenic Proteins and Cancer : Discovery, Design, and Development
	Pubbl/distr/stampa	Newark : , : John Wiley & Sons, Incorporated, , 2023 ©2023
	ISBN	9781394207145 139420714X 9781394207091 1394207093
	Edizione	[1st ed.]
	Descrizione fisica	1 online resource (391 pages)
	Altri autori (Persone)	WuYong-Jin
	Soggetti	Protein kinases - Inhibitors Oncogenes
	Lingua di pubblicazione	Inglese
	Formato	Materiale a stampa
	Livello bibliografico	Monografia

Nota di contenuto

Cover -- Title Page -- Copyright -- Contents -- Preface -- Chapter 1. Introduction -- 1.1 Types of Protein Kinases -- 1.2 Protein Kinase Domains -- 1.3 ATP-Binding Site -- 1.4 Types of Kinase Inhibitors -- 1.5 Brief History of Small-molecule kinase Inhibitors -- 1.6 Peak 12-Month Sales for Leading Kinase Inhibitors -- 1.7 Approved Kinase Inhibitors -- Chapter 2. BCR-ABL Inhibitors -- 2.1 Imatinib* -- 2.2 Nilotinib* -- 2.3 Dasatinib* -- 2.4 Bosutinib* -- 2.5 Ponatinib* -- 2.6 Olvermbatinib** -- 2.7 Asciminib* -- Chapter 3. BTK Inhibitors -- 3.1 Ibrutinib* -- 3.2 Acalabrutinib* -- 3.3 Zanubrutinib* -- 3.4 Tirabrutinib** -- 3.5 Orelabrutinib** -- Chapter 4. EGFR/HER Family Inhibitors -- 4.1 Gefitinib* -- 4.2 Erlotinib * -- 4.3 Icotinib** -- 4.4 Afatinib* -- 4.5 Dacomitinib* -- 4.6 Osimertinib* -- 4.7 Mobocertinib* -- 4.8 Lapatinib* -- 4.9 Tucatinib* -- 4.10 Neratinib* -- Chapter 5. VEGFR/Multikinase Inhibitors -- 5.1 Sorafenib* -- 5.2 Regorafenib* -- 5.3 Sunitinib* -- 5.4 Pazopanib* -- 5.5 Axitinib* -- 5.6 Nintedanib* -- 5.7 Apatinib** -- 5.8 Lenvatinib* -- 5.9 Tovozanib* -- Chapter 6. CDK4/6 Inhibitors -- 6.1 Palbociclib* -- 6.2 Ribociclib* -- 6.3 Abemaciclib* -- 6.4 Trilaciclib* -- Chapter 7. JAK Inhibitors -- 7.1 Tofacitinib* -- 7.2 Baricitinib* -- 7.3 Peficitinib** -- 7.4 Upadacitinib* -- 7.5 Delgocitinib** -- 7.6 Filgotinib** -- 7.7 Abrocitinib* -- 7.8 Ruxolitinib* -- 7.9 Fedratinib* -- 7.10 Pacritinib* -- 7.11 Ritlecitinib# -- 7.12 Brepocitinib# -- 7.13 Ropsacitinib# -- Chapter 8. Allosteric TYK2 Inhibitors -- 8.1 Deucravacitinib* -- Chapter 9. ALK/multikinase Inhibitors -- 9.1 Crizotinib* -- 9.2 Ceritinib* -- 9.3 Alectinib* -- 9.4 Brigatinib* -- 9.5 Lorlatinib* -- Chapter 10. BRAF/Multikinase Inhibitors -- 10.1 Vemurafenib* -- 10.2 Dabrafenib* -- 10.3 Encorafenib* -- Chapter 11. MEK Inhibitors -- 11.1 Trametinib* -- 11.2 Cobimetinib*.
11.3 Binimetinib* -- 11.4 Selumetinib* -- Chapter 12. RET/Multikinase Inhibitors -- 12.1 Vandetanib* -- 12.2 Cabozantinib* -- 12.3 Selpercatinib* -- 12.4 Pralsetinib* -- Chapter 13. FGFR Inhibitors -- 13.1 Erdafitinib* -- 13.2 Pemigatinib* -- 13.3 Infigratinib* -- 13.4 Futibatinib* -- Chapter 14. PI3K Inhibitors -- 14.1 Alpelisib* -- 14.2 Idelalisib* -- 14.3 Duvelisib* -- 14.4 Umbralisib* -- 14.5 Copanlisib* -- Chapter 15. TRK/Multikinase Inhibitors -- 15.1 Larotrectinib* -- 15.2 Entrectinib* -- 15.3 Repotrectinib# -- Chapter 16. MET Inhibitors -- 16.1 Capmatinib* -- 16.2 Tepotinib* -- Chapter 17. KIT/PDGFR/Multkinase Inhibitors -- 17.1 Avapritinib* -- 17.2 Ripretinib* -- Chapter 18. FLT3 Inhibitors -- 18.1 Midostaurin* -- 18.2 Gilteritinib* -- Chapter 19. mTOR Inhibitors -- 19.1 Sirolimus* and Analogs -- Chapter 20. Other Kinase Inhibitors -- 20.1 Netarsudil* -- 20.2 Belumosudil* -- 20.3 Fostamatinib* -- 20.4 Pexidartinib* -- Chapter 21. KRAS Inhibitors -- 21.1 Sotorasib* -- 21.2 Adagrasib* -- 21.3 JDQ443# -- Chapter 22. An Overview of the Discovery Process for Medically Useful Inhibitors of Oncogenic Protein Kinases -- 22.1 High-quality Leads -- 22.2 Integrating Substructures from Different High Quality Leads or Established Inhibitors -- 22.3 Variation of Hinge-binding Nucleus -- 22.4 Macrocyclization -- 22.5 Fragment-based Approach -- 22.6 Covalent Inhibitors -- 22.7 Strategic Structural Modification of Prior Drugs -- 22.8 Exploiting Specific Kinase Pocket to Optimize Selectivity -- 22.9 Solvent-exposed Appendages to Enhance Solubility and PK Properties -- Chapter 23. Targeted Molecular Anticancer Therapies - Successes and Challenges -- 23.1 The Beginning -- 23.2 Further Developments -- 23.3 Biomarker-driven Drug Development -- 23.4 Mitigation of Drug Resistance -- 23.5 Miscellaneous Approaches -- 23.6 Discovery Chemistry.
Appendix 1. First FDA Approvals by Year -- Appendix 2. Kinase/KRAS Inhibitors in Development -- Appendix 3. Visualization of Differentially

	Expressed Kinases in Cancer -- Appendix 4. M &amp -- A Transactions Driven by Oncology-focused Kinase and KRAS Inhibitors -- Appendix 5. Alphabetic List of Oncogenic Protein Inhibitors -- EULA.
Sommario/riassunto	This book provides a comprehensive examination of recent scientific advancements in cancer treatment, focusing on the development of molecular therapies targeting oncogenic proteins. Authored by E. J. Corey and Yong-Jin Wu, it explores the transformation in cancer therapy over the last 30 years through the introduction of nearly 80 FDA-approved synthetic compounds. These compounds specifically target mutated biomolecules responsible for cancer, differing significantly from older cytotoxic agents. The book discusses the role of protein kinases, a class of enzymes integral to cell growth regulation, in cancer proliferation, and highlights the pivotal scientific research enabling these breakthroughs. It is intended for researchers, medical professionals, and students interested in oncology, molecular biology, and drug development.